Evaluation of the Calcium Stone Former

1. Scales CD, Smith AC, Hanley JM et al. Prevalence of kidney stones in the United States. Eur Urol 2012; 62(1): 160–165. doi: 10.1016/j.eururo.2012.03.052.

2. Stamatelou KK, Francis ME, Jones CA et al. Time trends in reported prevalence of kidney stones in the United States: 1976–1994. Kidney Int 2003; 63(5): 1817–1823.

3. Sutherland JW, Parks JH, Coe FL. Recurrence after a single renal stone in a community practice. Miner Electrolyte Metab 1985; 11(4): 267–269.

4. Ljunghall S, Danielson BG. A prospective study of renal stone recurrences. Br J Urol 1984; 56(2): ­122–124.

5. Worcester EM. Stones from bowel disease. Endocrinol Metab Clin North Am 2002; 31(4): ­979–999.

6. Parks JH, Worcester EM, O’Connor RC et al. Urine stone risk factors in nephrolithiasis patients with and without bowel disease. Kidney Int 2003; 63(1): ­255–265.

7. Patel BN, Passman CM, Fernandez A et al. Prevalence of hyperoxaluria after bariatric surgery. J Urol 2009; 181(1): 161–166. doi: 10.1016/­j.juro.2008.09.028.

8. Asplin JR, Coe FL. Hyperoxaluria in kidney stone formers treated with modern bariatric surgery. J Urol 2007; 177(2): 565–569.

9. Coe F, Parks J. Nephrolithiasis: pathogenesis and treatment. 2nd ed. Chicago: Year Book Medical Publishers 1988: 109–110.

10. Curhan GC, Rimm EB, Willett WC et al. Regional variation in nephrolithiasis incidence and prevalence among United States men. J Urol 1994; 151(4):  ­838–841.

11. Soucie JM, Thun MJ, Coates RJ et al. Demographic and geographic variability of kidney stones in the United States. Kidney Int 1994; 46(3): 893–899.

12. Masterson JH, Jourdain VJ, Collard DA et al. Changes in urine parameters after desert exposure: assessment of stone risk in United States Marines transiently exposed to a desert environment. J Urol 2013; 189(1): 165–170. doi: 10.1016/j.juro.2012.08.097.

13. Borghi L, Meschi T, Amato F et al. Hot occupation and nephrolithiasis. J Urol 1993; 150(6): 1757–1760.

14. Curhan GC, Willett WC, Rimm EB et al. Prospective study of beverage use and the risk of kidney stones. Am J Epidemiol 1996; 143(3): 240–247.

15. Curham GC, Willett WC, Speizer FE et al. Beverage use and risk for kidney stones in women. Ann Intern Med 1998; 128(7): 534–540.

16. Heilberg IP, Goldfarb DS. Optimum nutrition for kidney stone disease. Adv Chronic Kidney Dis 2013; 20(2): 165–174. doi: 10.1053/j.ackd.2012.12.001.

17. Taylor EN, Curhan GC. Dietary calcium from dairy and nondairy sources, and risk of symptomatic kidney stones. J Urol 2013; 190(4): 1255–1259. doi: 10.1016/j.juro.2013.03.074.

18. Curhan GC, Willett WC, Knight EL et al. Dietary factors and the risk of incident kidney stones in younger women: Nurses’ Health Study II. Arch Intern Med 2004; 164(8): 885–891.

19. Holmes RP, Goodman HO, Assimos DG. Contribution of dietary oxalate to urinary oxalate excretion. Kidney Int 2001; 59(1): 270–276.

20. Breslau NA, Brinkley L, Hill KD et al. Relationship of animal protein-rich diet to kidney stone formation and calcium metabolism. J Clin Endocrinol Metab 1988; 66(1): 140–146.

21. Sakhaee K, Harvey JA, Padalino PK et al. The potential role of salt abuse on the risk for kidney stone formation. J Urol 1993; 150(1): 310–312.

22. Silver J, Friedlaender MM, Rubinger D et al. Sodium--dependent idiopathic hypercalciruia in renal-stone formers. The Lancet 1983; 322(8348): ­484–486.

23. Muldowney FP, Freaney R, Moloney MF. Importance of dietary sodium in the hypercalciuria syndrome. Kidney Int 1982; 22(3): 292–296.

24. Curhan GC, Willett WC, Rimm EB et al. Family history and risk of kidney stones. J Am Soc Nephrol 1997; 8(10): 1568–1573.

25. Coe FL, Parks JH, Moore ES. Familial idiopathic hypercalciuria. N Engl J Med 1979; 300(7): 337–340.

26. Goodman HO, Holmes RP, Assimos DG. Genetic factors in calcium oxalate stone disease. J Urol 1995; 153(2): 301–307.

27. Ahlstrand C, Tiselius HG. Urine composition and stone formation during treatment with acetazolamide. Scand J Urol Nephrol 1987; 21(3): 225–228.

28. Lamb EJ, Stevens PE, Nashef L. Topiramate increases biochemical risk of nephrolithiasis. Ann Clin Biochem 2004; 41: 166–169.

29. Welch BJ, Graybeal D, Moe OW et al. Biochemical and stone-risk profiles with topiramate treatment. Am J Kidney Dis 2006; 48(4): 555–563.

30. Auer BL, Auer D, Rodgers AL. The effect of ascorbic acid ingestion on the biochemical and physicochemical risk factors associated with calcium oxalate kidney stone formation. Clin Chem Lab Med 1998; 36(3): 143–147.

31. Jackson RD, LaCroix AZ, Gass M et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354(7): 669–683.

32. Saltel E, Angel JB, Futter NG et al. Increased prevalence and analysis of risk factors for indinavir neprholithasis. J Urol 2000; 164(6): 1895–1897.

33. Nadler RB, Rubenstein JN, Eggener SE et al. The etiology of urolithiasis in HIV infected patients. J Urol 2003; 169(2): 475–477.

34. Assimos DG, Langenstroer P, Leinbach RF et al. Guaifenesin- and ephedrine-induced stones. J Endourol 1999; 13(9): 665–667.

35. Ettinger B, Oldroyd NO, Sörgel F. Triamterene nephrolithiasis. JAMA 1980; 244(21): 2443–2445.

36. Pearle MS, Goldfarb DS, Assimos DG et al. Medical management of kidney stones: AUA guideline. J Urol 2014; 192(2): 316–324. doi: 10.1016/j.juro.2014.05.006.

37. Sheafor DH, Hertzberg BS, Freed KS et al. Nonenhanced helical CT and US in the emergency evaluation of patients with renal colic: prospective comparison. Radiology 2000; 217(3): 792–797.

38. Ulusan S, Koc Z, Tokmak N. Accuracy of sonography for detecting renal stone: Comparison with CT. J Clin Ultrasound 2007; 35(5): 256–261.

39. Smith-Bindman R, Aubin C, Bailitz J et al. Ultrasonography versus computed tomography for suspected nephrolithiasis. N Engl J Med 2014; 371(12): 1100–1110. doi: 10.1056/NEJMoa1404446.

40. Fulgham PF, Assimos DG, Pearle MS et al. Clinical effectiveness protocols for imaging in the management of ureteral calculous disease: AUA technology assessment. J Urol 2013; 189(4): 1203–1213. doi: 10.1016/j.juro.2012.10.031.

41. Chandhoke PS. Evaluation of the recurrent stone former. Urol Clin North Am 2007; 34(3): 315–322.

42. Kourambas J, Aslan P, Teh CL et al. Role of stone analysis in metabolic evaluation and medical treatment of nephrolithiasis. J Endourol 2001; 15(2): 181–186.

43. Bensalah K, Tuncel A, Raman JD et al. How physician and patient perceptions differ regarding medical management of stone disease. J Urol 2009; 182(3): 998–1004. doi: 10.1016/j.juro.2009.05.025.

44. Milose JC, Kaufman SR, Hollenbeck BK et al. Prevalence of 24-hour urine collection in high risk stone formers. J Urol 2014; 191(2): 376–380. doi: 10.1016/j.juro.2013.08.080.

45. Parks JH, Goldfisher E, Asplin JR et al. A single 24-hour urine collection is inadequate for the medical evaluation of nephrolithiasis. J Urol 2002; 167(4): 1607–1612.

46. Castle SM, Cooperberg MR, Sadetsky N et al. Ade­quacy of a single 24-hour urine collection for metabolic evaluation of recurrent nephrolithiasis. J Urol 2010; 184(2): 579–583. doi: 10.1016/j.juro.2010.03.129.

47. Pak CY, Peterson R, Poindexter JR. Adequacy of a single stone risk analysis in the medical evaluation of urolithiasis. J Urol 2001; 165(2): 378–381.

48. Borghi L, Schianchi T, Meschi T et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 2002; 346(2): 77–84.

49. Curhan GC, Willett WC, Rimm EB et al. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 1993; 328(12): 833–838.

50. Ortiz-Alvarado O, Miyaoka R, Kriedberg C et al. Pyridoxine and dietary counseling for the management of idiopathic hyperoxaluria in stone-forming patients. Urology 2011; 77(5): 1054–1058. doi: 10.1016/j.urology.2010.08.002.

51. Nikkilä M, Koivula T, Jokela H. Urinary citrate excretion in patients with urolithiasis and normal subjects. Eur Urol 1989; 16(5): 382–385.

52. Nicar MJ, Hill K, Pak CY. Inhibition by citrate of spontaneous precipitation of calcium oxalate in vitro. J Bone Miner Res 1987; 2(3): 215–220.

53. Hamm LL. Renal handling of citrate. Kidney Int 1990; 38(4): 728–735.

54. Coe FL, Kavalach AG. Hypercalciuria and hyper­uricosuria in patients with calcium nephrolithiasis. N Engl J Med 1974; 291(25): 1344–1350.

55. Ryall RL, Grover PK, Marshall VR. Urate and calcium stones – picking up a drop of mercury with one’s fingers? Am J Kidney Dis Off J Natl Kidney Found 1991; 17(4): 426–430.

56. Coe FL, Strauss AL, Tembe V et al. Uric acid sa­turation in calcium nephrolithiasis. Kidney Int 1980; 17(5): 662–668.

57. Borghi L, Meschi T, Amato F et al. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol 1996; 155(3): 839–843.

58. Maroni BJ, Steinman TI, Mitch WE. A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int 1985; 27(1): 58–65.

59. Hess B, Hasler-Strub U, Ackermann D et al. Metabolic evaluation of patients with recurrent idiopathic calcium nephrolithiasis. Nephrol Dial Transplant 1997; 12(7): 1362–1368.

60. Coe FL, Wise H, Parks JH et al. Proportional reduction of urine supersaturation during nephrolithiasis treatment. J Urol 2001; 166(4): 1247–1251.

61. Asplin JR. Evaluation of the kidney stone patient. Semin Nephrol 2008; 28(2): 99–110. doi: 10.1016/j.semnephrol.2008.01.001.